Facchini Peter J. 4

What Happened Peter J. Facchini, Chief Innovation Officer of Enveric Biosciences, was granted 25,000 restricted stock units (RSUs) on June 1, 2026. The award was recorded at $0.00 per share (no cash paid at grant); each vested RSU converts to one share of common stock when it vests.

Key Details

• Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (timely filing).
• Transaction type/code: Award/Grant (A); 25,000 RSUs granted at $0.00.
• Vesting: Per the company’s 2020 Long-Term Incentive Plan — 1/4 vests at one year, then 1/36 of the grant vests each month thereafter, with remaining units vesting on the fourth anniversary; vesting conditioned on continued employment (see footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Adjustment note: Amounts have been adjusted for a 12-for-1 reverse stock split effective Oct 28, 2025 (see footnote F2).

Context RSUs are a form of equity compensation that convert into common stock only as they vest; they are not an immediate open-market purchase or sale and do not necessarily indicate a near-term change in share ownership. This grant was a routine compensation award to an executive, filed promptly with the SEC.